Persistent LCMV infection is controlled by blockade of type I interferon signaling. - Wikidata - awgldk - TriplyDB

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

http://www.wikidata.org/entity/Q36808119

about

Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types The role of viral persistence in flavivirus biology The Dual Role of Exosomes in Hepatitis A and C Virus Transmission and Viral Immune Activation Identification of Candidate Predictors of Lupus Flare Molecular and cellular insights into T cell exhaustion Overcoming T cell exhaustion in infection and cancer Regulation of type I interferon responses Interferon-alpha, immune activation and immune dysfunction in treated HIV infection Immune responses to HCV and other hepatitis viruses Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA Decoding the complexity of type I interferon to treat persistent viral infections Reverse translation in tuberculosis: neutrophils provide clues for understanding development of active disease Infection-induced type I interferons activate CD11b on B-1 cells for subsequent lymph node accumulation.Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses Innate and Adaptive Immune Regulation During Chronic Viral Infections Disease-promoting effects of type I interferons in viral, bacterial, and coinfections Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance Type I Interferons Induce T Regulatory 1 Responses and Restrict Humoral Immunity during Experimental Malaria Murine Cytomegalovirus Disrupts Splenic Dendritic Cell Subsets via Type I Interferon-Dependent and -Independent Mechanisms.Type I IFN signaling facilitates the development of IL-10-producing effector CD8+ T cells during murine influenza virus infection.Type I interferon suppresses virus-specific B cell responses by modulating CD8(+) T cell differentiation Type I interferon is a therapeutic target for virus-induced lethal vascular damage.Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection.Dynamic functional modulation of CD4+ T cell recall responses is dependent on the inflammatory environment of the secondary stimulus.Pathogenic potential of interferon αβ in acute influenza infection Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection.Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity.Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis.Loss of the death receptor CD95 (Fas) expression by dendritic cells protects from a chronic viral infection.Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.Type I interferon in the pathogenesis of lupus.Immunologic strategies for HIV-1 remission and eradication.Increased antigen presentation but impaired T cells priming after upregulation of interferon-beta induced by lipopolysaccharides is mediated by upregulation of B7H1 and GITRL Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design.IFNαR signaling in effector but not regulatory T cells is required for immune dysregulation during type I IFN-dependent inflammatory disease.IFN-λ exerts opposing effects on T cell responses depending on the chronicity of the virus infection.Sex-based differences in HIV type 1 pathogenesis

P2860

Q21131160-E89D3914-6502-4841-A2CF-FD7D4BD0BCD2 Q22809893-0B475E08-E5C6-43C3-AE29-53932AEBFD4D Q26773325-A97E2F7F-D142-4B31-B90C-30D2C28B3192 Q26795372-4BA06CC4-DA1C-4CC7-ADE5-158EAF678B46 Q26800047-ABD5FD49-E0B0-4007-A6C0-27849BB1DD62 Q26829885-BF596C4C-6274-442C-8BAA-59631E94A565 Q26853177-58DC9998-0087-4C31-A0C5-6502BEE9ED83 Q26861003-3EACCBB1-2D25-4D06-8990-EEDC4FC691D3 Q26866955-3B8A1616-FAF1-4A8C-9CE2-2838F946FE44 Q27022855-E7EA6C82-2325-485A-A4A9-A04F4BD72121 Q27023801-ADDE3B8C-732A-430D-BAE7-112C27F35D35 Q27027976-C43556C2-A5E9-42F4-A07A-7C3307A1DE1E Q27316718-94139DBD-272E-4F1D-AAE8-A1409ED31DC0 Q27320523-AD05167F-8ACB-4E23-B39D-15BF7A8DD7BF Q28079141-1CD0FDA9-5FCA-4D4E-AB13-CA9310188394 Q28079717-9CB919D5-0859-45E0-810A-F0F31B1DE8EF Q28082841-99AFDB88-5C3D-4451-84CA-A6C8E53DFD94 Q28540848-6D6726F7-FE18-407A-9A7A-922A7E95FBEF Q28554673-D6A029F1-2BBE-45E5-AF92-5056E19187DA Q30252883-1A3693B8-F822-437F-93C6-608D0C24E6CA Q30275794-961CE128-6834-48F0-8567-81C662229231 Q30827049-3DD2681B-935B-426E-AD21-097BCB54DE5F Q33415686-B893FCE4-D566-4361-A1F1-E9458E185BDB Q33569835-D12FB7DB-DDA3-4F40-8E6F-D6E558718955 Q33650695-DC049FB6-1A5C-48D9-AEBD-DC8596BE3D63 Q33663298-FE8C6D6D-971F-4696-91E3-7C3A7DAB8EB2 Q33665625-51AAEB43-F7DC-42CB-B233-C95473F8450C Q33685904-79BF37E3-392B-46BD-82F2-D0B8CF42E939 Q33731047-615FD7D3-92D4-45A0-B45A-0A08345F125C Q33745372-88FF8CE8-F833-4AC5-86F6-8D6AFB85EE4B Q33767444-72973B1A-FF90-4413-A76A-A60AF9292857 Q33797446-5ECDF0F4-2900-4C38-96E0-3BCAB36285CA Q33852174-D21B7834-F4F6-42AA-B830-D9445E91208F Q33896523-C21B8D40-9C7D-4F8E-9B1C-45D79539C610 Q34075613-B2B9D93B-1C2C-4A4C-AD8E-E584330E6412 Q34089124-43D478A7-4D59-4A53-9B85-42C7252E6009 Q34106393-749EEF4E-EDA8-410A-858E-4ED8E57AB0CB Q34146449-36679C89-C02A-4759-81B0-A3709E72283D Q34147632-1FBAE99D-2BE7-46E0-9F22-D3B3605BE6DA Q34148475-040570C4-B4D6-4E85-A5EE-ABF400DE1B45

P2860

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

http://www.wikidata.org/entity/Q36808119

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

@ast

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

@en

type

label

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

@ast

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

@en

prefLabel

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

@ast

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

@en

P1433

Q36808119-EEA4B667-7084-42BB-AA04-64618FF70902

P1476

Q36808119-A7AEE2B5-80DD-463D-B577-DB1427C3C614

P2093

Q36808119-4CBDCCDF-1465-46DF-BF37-CA15826CC923

Q36808119-57589C72-978B-4ED6-BA22-2A2401728321

Q36808119-69E2C4FF-DF83-4927-BF64-F8F02CFF9F29

Q36808119-84C40437-E4B7-48E8-B297-A887A30586AF

Q36808119-8C74AA87-D5C2-4EF7-9B58-E5139FCBFBBB

Q36808119-97E18F16-33A1-4530-B7AE-9F3A1C39D583

Q36808119-AE485207-B9A7-4BDE-8AA5-3CA19FF2D6B2

Q36808119-B8B400E0-E982-4242-A630-6A2545FB014E

Q36808119-C07E02B8-8620-4C81-8696-F199E14B864C

P2860

Q36808119-042228D3-E9F7-4233-A7F3-6B11A6D74612

Q36808119-0B26776D-567E-4C2A-9CF9-36BD4A2709BC

Q36808119-107BDD98-563F-4177-A8CF-4D3A59E417F6

Q36808119-135CB044-4CBF-4CAF-9412-578ED28F1EB8

Q36808119-140DBBCE-120E-4785-91B6-FA5F835CAE6B

Q36808119-1A564329-693E-40F1-BCAB-9F8B02892641

Q36808119-1EB4FDE6-D0AB-4677-9C6B-2EEB50499ED4

Q36808119-2692A8AB-EA41-469D-9F54-C7DAA4F29755

Q36808119-298BD80C-BA9D-4136-BE86-316F908BA862

Q36808119-30B8F35B-4857-4080-AEF2-67CBF3CED812

P304

Q36808119-12924F49-05CB-4DA5-B296-0BAA47A41DC3

P31

Q36808119-631F5490-B4D5-4713-A05A-67EC95E41834

P356

Q36808119-F79841F9-C15E-474F-B9B5-959A6CA71C26

P407

Q36808119-E7D0E9E8-919D-4105-A2CB-0EDC228273E3

P433

Q36808119-E10D5301-B296-47DC-8498-DEE5320E3EC4

P478

Q36808119-00432103-96E8-4154-BBC2-3539E7017379

P577

Q36808119-ABC446C4-AB11-4D1C-AD34-73152EBDE43D

P698

Q36808119-7011CB68-B8B2-4707-8372-F6757FAC344D

P932

Q36808119-427A6C88-AB85-4026-9CD3-0A2A0DAD39C6

P356

SCIENCE.1235214

P1433

P1476

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

@en

P2093

Andrew M Lee

http://www.w3.org/2001/XMLSchema#string

Brian M Sullivan

http://www.w3.org/2001/XMLSchema#string

Cherie Ng

http://www.w3.org/2001/XMLSchema#string

John R Teijaro

http://www.w3.org/2001/XMLSchema#string

Juan Carlos de la Torre

http://www.w3.org/2001/XMLSchema#string

Kathleen C F Sheehan

http://www.w3.org/2001/XMLSchema#string

Megan Welch

http://www.w3.org/2001/XMLSchema#string

Michael B A Oldstone

http://www.w3.org/2001/XMLSchema#string

Robert D Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

Immune activation and inflammation in HIV-1 infection: causes and consequences

A diverse range of gene products are effectors of the type I interferon antiviral response

Viral immune evasion due to persistence of activated T cells without effector function

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

Interleukin-10 determines viral clearance or persistence in vivo

Virus interference. I. The interferon

Mechanisms of type-I- and type-II-interferon-mediated signalling

Restoring function in exhausted CD8 T cells during chronic viral infection

Type I interferons in host defense

T-cell exhaustion: characteristics, causes and conversion.

P304

207-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1235214

http://www.w3.org/2001/XMLSchema#string

P407

P433

6129

http://www.w3.org/2001/XMLSchema#string

P478

340

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23580529

http://www.w3.org/2001/XMLSchema#string

P932

3640797

http://www.w3.org/2001/XMLSchema#string